This review examines the high clinical overlap between major depressive disorder (MDD) and substance use disorders (SUD), emphasizing that comorbidity is common, complex, and associated with worse outcomes than either condition alone. Between one-quarter and one-third of people with any mental illness also have an SUD, and major depression is highly prevalent among people with drug use disorders. Patients with both MDD and SUD often experience earlier depression onset, greater psychosocial and medical burden, higher suicide risk, poorer prognosis, and more complicated treatment needs. The review outlines several possible explanations for the overlap, including self-medication, drug-induced depressive symptoms, shared genetic or developmental vulnerabilities, and the role of trauma and chronic stress in shaping both mood and substance-use risk.

The article also reviews shared neurobiological pathways involved in depression and addiction, particularly brain regions and circuits related to reward, stress, motivation, and emotional regulation. Stress may increase vulnerability to drug intake, while withdrawal can trigger depressive symptoms such as dysphoria, anxiety, irritability, and anhedonia, reinforcing a cycle of substance use and mood worsening. The authors note that although much is known about depression and addiction separately, less is known about the specific neurobiology of comorbidity, partly because patients are highly heterogeneous. They conclude that better understanding the underlying mechanisms of dual diagnosis is essential for improving diagnosis, tailoring treatment, and addressing both conditions together rather than in isolation.

Reference: Calarco CA, Lobo MK. Depression and substance use disorders: Clinical comorbidity and shared neurobiology. Int Rev Neurobiol. 2021;157:245-309. doi: 10.1016/bs.irn.2020.09.004. Epub 2020 Nov 17. PMID: 33648671.

This scoping review identified therapeutic guidelines that can support self-management of major depressive disorder (MDD) symptoms in adults. The authors searched 12 scientific databases and 5 gray-literature sources, ultimately including 62 studies published between 2011-2023. The review mapped guidance across common depressive symptoms such as sleep changes, appetite and weight changes, guilt, irritability, anhedonia, fatigue, and low self-esteem. Seven major self-management categories emerged: psychotherapy, healthy habits, integrative and complementary practices, relaxation techniques, consultation with a health professional, pharmacologic therapy, and leisure or pleasurable activities.

Psychotherapy was the most frequently identified category, followed by healthy habits such as physical activity and nutrition, and integrative approaches such as mindfulness, yoga, music therapy, acupuncture, phototherapy, tai chi, and aromatherapy. The review emphasizes that self-management does not mean patients manage depression alone. Rather, it should be supported by clinicians, families, caregivers, and community resources, especially because MDD can affect motivation, cognition, energy, and follow-through. The authors conclude that clear, individualized therapeutic guidance can help patients build knowledge, skills, autonomy, adherence, symptom awareness, and relapse-prevention strategies as part of multidisciplinary depression care.

Reference: de Campos Tibúrcio P, Maria Marcheti P, Miori Pascon D, et al. Therapeutic guidelines for the self-management of major depressive disorder: scoping review. Interact J Med Res. 2025 Mar 6;14:e63959. doi: 10.2196/63959. PMID: 40053745; PMCID: PMC11926446.

The FDA approved Flow Neuroscience’s FL-100, an at-home transcranial direct current stimulation device for adults with moderate-to-severe major depressive disorder (MDD) who are not considered medication-resistant. The headset delivers stimulation to the dorsolateral prefrontal cortex, a brain region involved in mood regulation, and can be used alone or alongside other treatments. Approval was based on the remote, multicenter, double-blind, randomized Empower Phase 2 study, which included 174 adults with unipolar MDD and found that 58% achieved remission after 10 weeks.

Treatment typically involves a 12-week course, with five 30-minute sessions per week for the first 3 weeks, followed by two to three sessions weekly for the remaining nine weeks. The device is guided by a digital app or clinician supervision, with generally mild and temporary adverse effects such as skin irritation, headache, and tingling at the electrode sites; skin burns have occurred when pads were reused or dried out. Flow plans to launch FL-100 in the United States in the second quarter of 2026 as a prescription-only treatment, with an estimated retail price of $500-$800 and insurance details expected in early 2026.

Reference: Walters J. FDA approves first at-home brain stimulation device for treatment of depression. Psychiatric Times. Published December 12, 2025. Accessed June 30, 2026. https://www.psychiatrictimes.com/view/fda-approves-first-at-home-brain-stimulation-device-for-treatment-of-depression